Kindred Biosciences Company Profile (NASDAQ:KIN)

About Kindred Biosciences

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KIN
  • CUSIP:
Key Metrics:
  • Previous Close: $6.00
  • 50 Day Moving Average: $6.10
  • 200 Day Moving Average: $5.03
  • 52-Week Range: $3.12 - $7.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.44
  • P/E Growth: -0.35
  • Market Cap: $119.35M
  • Outstanding Shares: 19,891,000
  • Beta: 0.54
Profitability:
  • Return on Equity: -33.34%
  • Return on Assets: -32.23%
Debt:
  • Current Ratio: 23.24%
  • Quick Ratio: 23.24%
Additional Links:
Companies Related to Kindred Biosciences:

Analyst Ratings

Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.25 (21.85% upside)

Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
Show:
DateFirmActionRatingPrice TargetDetails
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50View Rating Details
5/17/2016BMO Capital MarketsReiterated RatingMarket Perform$5.00 -> $7.00View Rating Details
8/13/2015Roth CapitalReiterated RatingHoldView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Kindred Biosciences (NASDAQ:KIN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017        
11/7/2016Q316($0.34)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
5/5/2016Q116($0.32)($0.27)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
8/10/2015Q2($0.44)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.41)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.43)($0.34)ViewN/AView Earnings Details
11/13/2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.19)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.19 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS

Dividends

Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kindred Biosciences (NASDAQ:KIN)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 66.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.00View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.00View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.94View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.45View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
DateHeadline
streetinsider.com logoKindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application (NASDAQ:KIN)
www.streetinsider.com - February 6 at 11:19 PM
reuters.com logoBRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz (NASDAQ:KIN)
www.reuters.com - February 6 at 6:17 PM
us.rd.yahoo.com logo9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted) (NASDAQ:KIN)
us.rd.yahoo.com - February 6 at 10:21 AM
finance.yahoo.com logoKindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz™ New Animal Drug Application (NASDAQ:KIN)
finance.yahoo.com - February 6 at 10:21 AM
4-traders.com logoNetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market (NASDAQ:KIN)
www.4-traders.com - January 27 at 5:57 AM
kcregister.com logoLive Nation Entertainment, Inc. (NYSE:LYV) acquired majority interest in BottleRock Napa Valley music (NASDAQ:KIN)
www.kcregister.com - January 17 at 11:33 PM
zacks.com logoKindred Biosciences (KIN) Looks Good: Stock Jumps 9.5% (NASDAQ:KIN)
www.zacks.com - January 16 at 8:35 AM
seekingalpha.com logoKindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of Pets (NASDAQ:KIN)
seekingalpha.com - January 14 at 12:26 AM
marketexclusive.com logoInsider Trading Activity Kindred Biosciences, Inc. (NASDAQ:KIN) – Major Shareholder Bought 110,617 shares of Stock (NASDAQ:KIN)
marketexclusive.com - January 8 at 5:55 PM
marketexclusive.com logoAnalyst Activity – Feltl & Co. Initiates Coverage On Kindred Biosciences (NASDAQ:KIN) With a Strong-Buy (NASDAQ:KIN)
marketexclusive.com - January 3 at 9:42 PM
marketexclusive.com logoKINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:KIN)
marketexclusive.com - December 21 at 6:59 PM
biz.yahoo.com logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:KIN)
biz.yahoo.com - December 20 at 11:45 AM
feeds.reuters.com logoBRIEF-Kindred Biosciences entered into an at market issuance sales agreement (NASDAQ:KIN)
feeds.reuters.com - December 19 at 5:40 PM
News IconShould You Buy Kindred Biosciences Inc (KIN)? (NASDAQ:KIN)
feedproxy.google.com - December 16 at 3:13 PM
News IconAnimal Antibiotics and Antimicrobials Market Worth 4.73 Billion USD by 2021 (NASDAQ:KIN)
www.bio-medicine.org - December 12 at 11:19 PM
marketexclusive.com logoKINDRED BIOSCIENCES, INC. (NASDAQ:KIN) Files An 8-K Regulation FD Disclosure (NASDAQ:KIN)
marketexclusive.com - December 7 at 6:14 PM
biz.yahoo.com logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:KIN)
biz.yahoo.com - December 7 at 6:14 PM
capitalcube.com logoKindred Biosciences, Inc. :KIN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 (NASDAQ:KIN)
www.capitalcube.com - December 5 at 6:23 PM
reuters.com logoBRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention (NASDAQ:KIN)
www.reuters.com - November 29 at 4:18 PM
finance.yahoo.com logoKindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention (NASDAQ:KIN)
finance.yahoo.com - November 29 at 4:18 PM
finance.yahoo.com logoKindred Biosciences to Present at 9th Annual LD Micro Investor Conference (NASDAQ:KIN)
finance.yahoo.com - November 18 at 5:25 PM
seekingalpha.com logoTracking Seth Klarman's Baupost Group Holdings - Q3 2016 Update (NASDAQ:KIN)
seekingalpha.com - November 16 at 9:29 AM
prnewswire.com logoKindred Biosciences Announces Third Quarter 2016 Financial Results (NASDAQ:KIN)
www.prnewswire.com - November 7 at 9:38 AM
finance.yahoo.com logoCoverage initiated on Kindred Biosciences by Ladenburg Thalmann (NASDAQ:KIN)
finance.yahoo.com - November 1 at 6:08 PM
finance.yahoo.com logoKindred Biosciences Is 'Setting The Pace In Animal Health Biologics' (NASDAQ:KIN)
finance.yahoo.com - November 1 at 6:08 PM
finance.yahoo.com logoKindred Biosciences to Announce Third Quarter 2016 Financial Results (NASDAQ:KIN)
finance.yahoo.com - October 24 at 11:07 AM
thestreet.com logo2 Bargains That Are Hiding in Plain Sight (NASDAQ:KIN)
realmoney.thestreet.com - October 11 at 6:04 PM
News IconKindred Biosciences gets US FDA technical section complete letter of effectiveness for Zimeta (NASDAQ:KIN)
www.pharmabiz.com - October 6 at 11:17 AM
News IconKindred Bio Receives Approval Of Effectiveness Technical Section From FDA For Zimeta New Animal Drug Application (NASDAQ:KIN)
www.biospace.com - October 5 at 5:45 PM
finance.yahoo.com logoKindred Biosciences (KIN) Looks Good: Stock Gains 5.6% (NASDAQ:KIN)
finance.yahoo.com - October 4 at 10:36 AM
streetinsider.com logoKindred Biosciences (KIN) Submits Safety Technical Section to FDA Related to Mirataz NADA (NASDAQ:KIN)
www.streetinsider.com - September 30 at 10:58 AM
News IconKindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launc... (NASDAQ:KIN)
ih.advfn.com - September 30 at 10:58 AM
fxpips.com logoStocks Gapping Up today – PTGX, TCON, TTOO, EFUT, MIFI, IMPV, TWTR (NASDAQ:KIN)
www.fxpips.com - September 27 at 10:27 AM
finance.yahoo.com logoKindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference (NASDAQ:KIN)
finance.yahoo.com - September 21 at 9:58 AM
finance.yahoo.com logo5 Breakout Stocks for Excellent Returns (NASDAQ:KIN)
finance.yahoo.com - September 16 at 12:28 PM
News IconKindred Bio To Participate In A BIO Animal Biotech Summit Panel (NASDAQ:KIN)
www.biospace.com - September 15 at 8:52 PM
finance.yahoo.com logoKindred Biosciences to Participate in a BIO Animal Biotech Summit Panel (NASDAQ:KIN)
finance.yahoo.com - September 15 at 8:52 PM
finance.yahoo.com logoKindred Biosciences' (KIN) Shares March Higher, Can It Continue? (NASDAQ:KIN)
finance.yahoo.com - September 14 at 5:55 PM
finance.yahoo.com logoKindred Biosciences (KIN) Jumps: Stock Moves 5.7% Higher (NASDAQ:KIN)
finance.yahoo.com - August 25 at 10:51 AM
streetinsider.com logoKindred Biosciences (KIN) Submits Mirataz's New Animal Drug Application Technical Section to FDA (NASDAQ:KIN)
www.streetinsider.com - August 23 at 10:14 AM
prnewswire.com logoKindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA (NASDAQ:KIN)
www.prnewswire.com - August 23 at 10:14 AM
finance.yahoo.com logoEdited Transcript of KIN earnings conference call or presentation 8-Aug-16 8:30pm GMT (NASDAQ:KIN)
finance.yahoo.com - August 16 at 5:59 PM
4-traders.com logoKINDRED BIOSCIENCES, INC. : Results of Operations and Financial Condition (form 8-K) (NASDAQ:KIN)
www.4-traders.com - August 10 at 8:48 AM
News IconKindred Biosciences Announces Second Quarter 2016 Financial Results (NASDAQ:KIN)
ih.advfn.com - August 10 at 8:48 AM
sg.finance.yahoo.com logoKindred Bio reports 2Q loss (NASDAQ:KIN)
sg.finance.yahoo.com - August 8 at 6:03 PM
biz.yahoo.com logoQ2 2016 Kindred Biosciences Inc Earnings Release - After Market Close (NASDAQ:KIN)
biz.yahoo.com - August 8 at 10:32 AM
capitalcube.com logoKinepolis Group NV :KIN-BE: Earnings Analysis: For the six months ended December 31, 2015 : August 4, 2016 (NASDAQ:KIN)
www.capitalcube.com - August 4 at 8:54 AM
News IconKindred Biosciences to Announce Second Quarter 2016 Financial Results (NASDAQ:KIN)
www.kait8.com - July 26 at 6:04 PM
capitalcube.com logoKinepolis Group NV :KIN-BE: Earnings Analysis: 2015 By the Numbers : July 25, 2016 (NASDAQ:KIN)
www.capitalcube.com - July 25 at 1:45 AM
finance.yahoo.com logoKindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates (NASDAQ:KIN)
finance.yahoo.com - June 14 at 4:02 PM

Social

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?

3 brokers have issued 12 month price objectives for Kindred Biosciences' stock. Their predictions range from $7.00 to $7.50. On average, they anticipate Kindred Biosciences' share price to reach $7.25 in the next year.

When will Kindred Biosciences announce their earnings?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns Kindred Biosciences stock?

Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.71%), EcoR1 Capital LLC (2.87%), Renaissance Technologies LLC (1.77%), Royce & Associates LP (0.74%), Osborn Williams & Donohoe LLC (0.32%) and GRT Capital Partners L.L.C. (0.24%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc and Raymond Townsend.

Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?

Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and GRT Capital Partners L.L.C..

Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?

Kindred Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Renaissance Technologies LLC. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend.

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kindred Biosciences stock cost?

One share of Kindred Biosciences stock can currently be purchased for approximately $5.95.

Kindred Biosciences (NASDAQ:KIN) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Earnings History Chart

Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)

Dividend History Chart

Dividend Payments by Quarter for Kindred Biosciences (NASDAQ:KIN)

Last Updated on 2/22/2017 by MarketBeat.com Staff